COGT
Price
$34.95
Change
+$1.55 (+4.64%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
5.37B
117 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$9.00
Change
+$0.26 (+2.97%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
705.21M
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COGT vs REPL

Header iconCOGT vs REPL Comparison
Open Charts COGT vs REPLBanner chart's image
Cogent Biosciences
Price$34.95
Change+$1.55 (+4.64%)
Volume$50.01K
Capitalization5.37B
Replimune Group
Price$9.00
Change+$0.26 (+2.97%)
Volume$32.28K
Capitalization705.21M
COGT vs REPL Comparison Chart in %
COGT
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
COGT vs. REPL commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (COGT: $34.95 vs. REPL: $8.99)
Brand notoriety: COGT and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 117% vs. REPL: 30%
Market capitalization -- COGT: $5.37B vs. REPL: $705.21M
COGT [@Biotechnology] is valued at $5.37B. REPL’s [@Biotechnology] market capitalization is $705.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • COGT’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, both COGT and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • COGT’s TA Score: 5 bullish, 4 bearish.
  • REPL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, COGT is a better buy in the short-term than REPL.

Price Growth

COGT (@Biotechnology) experienced а -0.88% price change this week, while REPL (@Biotechnology) price change was -0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

COGT is expected to report earnings on Mar 17, 2026.

REPL is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($5.37B) has a higher market cap than REPL($705M). COGT YTD gains are higher at: 348.077 vs. REPL (-25.764). REPL has higher annual earnings (EBITDA): -268.18M vs. COGT (-299.34M). REPL has more cash in the bank: 403M vs. COGT (238M). COGT has less debt than REPL: COGT (60.7M) vs REPL (76.3M). COGT (0) and REPL (0) have equivalent revenues.
COGTREPLCOGT / REPL
Capitalization5.37B705M761%
EBITDA-299.34M-268.18M112%
Gain YTD348.077-25.764-1,351%
P/E RatioN/AN/A-
Revenue00-
Total Cash238M403M59%
Total Debt60.7M76.3M80%
FUNDAMENTALS RATINGS
COGT vs REPL: Fundamental Ratings
COGT
REPL
OUTLOOK RATING
1..100
2488
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
25100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3436
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for COGT (81) in the Miscellaneous industry. This means that REPL’s stock grew somewhat faster than COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (25) in the Miscellaneous industry is significantly better than the same rating for REPL (100) in the Biotechnology industry. This means that COGT’s stock grew significantly faster than REPL’s over the last 12 months.

REPL's SMR Rating (97) in the Biotechnology industry is in the same range as COGT (99) in the Miscellaneous industry. This means that REPL’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (34) in the Miscellaneous industry is in the same range as REPL (36) in the Biotechnology industry. This means that COGT’s stock grew similarly to REPL’s over the last 12 months.

COGT's P/E Growth Rating (100) in the Miscellaneous industry is in the same range as REPL (100) in the Biotechnology industry. This means that COGT’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTREPL
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
COGT
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAILX21.28N/A
N/A
BlackRock International Instl
JIAIX9.47N/A
N/A
JHancock Multi-Asset High Income I
NMAVX11.96N/A
N/A
Nuance Mid Cap Value Investor
TGIPX43.92N/A
N/A
T. Rowe Price Spectrum Mod Gr Allc I
VEXAX152.09N/A
N/A
Vanguard Extended Market Index Admiral

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
+4.64%
SPHDF - COGT
63%
Loosely correlated
N/A
IMNM - COGT
49%
Loosely correlated
-1.06%
ENGN - COGT
47%
Loosely correlated
-1.89%
CRNX - COGT
45%
Loosely correlated
-0.23%
REPL - COGT
42%
Loosely correlated
+2.86%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+2.86%
ELVAF - REPL
60%
Loosely correlated
N/A
IMNN - REPL
57%
Loosely correlated
-8.07%
SNDX - REPL
49%
Loosely correlated
-2.22%
KYMR - REPL
45%
Loosely correlated
+0.95%
NRIX - REPL
43%
Loosely correlated
+13.09%
More